Novo Nordisk launches Victoza for the treatment of type 2 diabetes
Posted Nov 04 2009 10:05pm
Novo Nordisk have announced that Victoza, the first once-daily human Glucagon-like peptide-1 (GLP-1) analogue which regulates blood sugar in a glucose-dependent manner, is available for people with type 2 diabetes in the UK. Victoza is the only human GLP-1 analogue with 97% homology to natural human GLP-1 peptide.
Victoza represents an important advance in diabetes treatment because it helps patients maintain normal blood sugar levels with a once-daily injection that can be taken at any time of day, irrespective of meals. Victoza works with the body to lower glucose levels by stimulating the release of insulin only when glucose levels become too high. The benefit to the patient is that there is reduced risk of blood sugar becoming too low (hypoglycaemia).
Victoza can help patients achieve weight loss, by increasing satiety and delaying gastric empting, and thus reducing caloric intake. This is an important factor in treating patients with type 2 diabetes as many patients are overweight. Furthermore, weight gain is a side effect of some common treatment regimens for type 2 diabetes, thus increasing the risk of obesity-related illnesses.
“Our goal for the development of Victoza was to find the best way to help people with type 2 diabetes maintain control over their glucose levels in a manageable way with reduced risk of hypoglycaemia”, says Viggo Birch, Managing Director of Novo Nordisk UK and Ireland. “Victoza is an important new addition to the portfolio designed to support our mission to defeat diabetes, and we are proud to make this product available to patients in the UK”.